PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER

被引：0
|
作者：
Secord, A. Alvarez [1 ]
McCollum, M. [2 ]
Davidson, B. [3 ]
Broadwater, G. [4 ]
Squatrito, R. [2 ]
Havrilesky, L. [3 ]
Gabel, A. [5 ]
Nixon, A. [6 ]
Duska, L. [5 ]
机构：
[1] Duke Univ, Med Ctr, Obstet & Gynecol, Durham, NC USA
[2] Virginia Oncol Associates, Gynecol Oncol, Norfolk, VA USA
[3] Duke Canc Inst, Obstet & Gynecol, Durham, NC USA
[4] Duke Canc Inst, Stat, Durham, NC USA
[5] Univ Virginia, Obstet & Gynecol, Charlottesville, VA USA
[6] Duke Canc Inst, Med, Durham, NC USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0116
引用
收藏
页码：457 / 457
页数：1
相关论文
共 50 条
  • [1] Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
    Secord, Angeles Alvarez
    McCollum, Michael
    Davidson, Brittany A.
    Broadwater, Gloria
    Squatrito, Robert
    Havrilesky, Laura J.
    Gabel, Anne C.
    Starr, Mark D.
    Brady, J. Chris
    Nixon, Andrew B.
    Duska, Linda R.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 555 - 561
  • [2] Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.
    Davidson, Brittany Anne
    Squatrito, Robert
    Duska, Linda R.
    Havrilesky, Laura Jean
    Schwager, Nyssa
    McCollum, Michael
    Arapovic, Sanja
    Secord, Angeles Alvarez
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer
    Ghosh, Jaya
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 7 - U37
  • [4] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma
    Takahashi, Masamichi
    Kawashima, Satoshi
    Otake, Yohei
    Satomi-Tsushita, Natsuko
    Kuchiba, Aya
    Sadachi, Ryo
    Ohata, Keiko
    Ozawa, Hitoshi
    Yonemori, Kan
    Nagane, Motoo
    Arakawa, Yoshiki
    Mukasa, Akitake
    Tanaka, Shota
    Nishikawa, Ryo
    Muragaki, Yoshihiro
    Masutomi, Kenkichi
    Ichimura, Koichi
    Nakamura, Kenichi
    Narita, Yoshitaka
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
  • [7] Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer
    Strauss, H. G.
    Henze, A.
    Teichmann, A.
    Karbe, I.
    Baumgart, A.
    Thomssen, C.
    Koelbl, H.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 612 - 616
  • [8] Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    Tillmanns, Todd D.
    Lowe, M. Patrick
    Walker, Mark S.
    Stepanski, Edward J.
    Schwartzberg, Lee S.
    GYNECOLOGIC ONCOLOGY, 2013, 128 (02) : 221 - 228
  • [9] Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer
    Bodurka, DC
    Levenback, C
    Wolf, JK
    Gano, J
    Wharton, JT
    Kavanagh, JJ
    Gershenson, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 291 - 297
  • [10] A phase II trial of pembrolizumab in combinationwith bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Zsiros, E.
    Frederick, P. J.
    Akers, S. N.
    Attwood, K.
    Wang, K.
    Lele, S. B.
    Odunsi, K.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 23 - 23
12345